AMEX · Biotechnology
ARMP (ARMP) Stock
$5.28
-4.17%
AMEX: ARMP
Healthcare
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Armata Pharma Reaches FDA Agreement on Pediatric Study Plan for AP-SA02
MT Newswires · Jul 13, 2026
Armata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Complicated Staphylococcus aureus Bacteremia
PR Newswire · Jul 13, 2026
Sector Update: Healthcare Stocks Mixed Pre-Bell Tuesday
MT Newswires · Jun 23, 2026
Armata Pharmaceuticals Receives Additional $2.5 Million in Funding From US Department of Defense
MT Newswires · Jun 23, 2026
Armata Pharmaceuticals Receives $2.5 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support AP-SA02
PR Newswire · Jun 23, 2026
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Insiders Held68.55%
Institutions Held10.46%
Institutions Float Held33.25%
Peer Comparison
About ARMP
ARMP is led by CEO Deborah L. Birx, employs 60 people, headquartered in US, publicly traded since 1994.
ARMP stock trades at $5.28 with a market capitalization of $193.83M. The stock is valued at a price-to-earnings (P/E) ratio of -1.03, price-to-book of -0.87, price-to-sales of 60.65. Over the past 52 weeks the stock has ranged between $2.40 and $16.34, and currently trades 67.7% below its 52-week high.
On profitability, ARMP generates a return on equity (ROE) of 89.70% — well above the market average, a sign of a high-quality business, return on capital employed of 25.40%, an operating margin of -620.00%, a net profit margin of -95.54%.